0.72
+0.0539(+8.04%)
Currency In USD
| Previous Close | 0.67 |
| Open | 0.67 |
| Day High | 0.76 |
| Day Low | 0.67 |
| 52-Week High | 1.43 |
| 52-Week Low | 0.24 |
| Volume | 1.01M |
| Average Volume | 1.46M |
| Market Cap | 42.57M |
| PE | -0.63 |
| EPS | -1.15 |
| Moving Average 50 Days | 0.78 |
| Moving Average 200 Days | 0.53 |
| Change | 0.05 |
If you invested $1000 in BioAtla, Inc. (BCAB) since IPO date, it would be worth $23.34 as of December 24, 2025 at a share price of $0.724. Whereas If you bought $1000 worth of BioAtla, Inc. (BCAB) shares 3 years ago, it would be worth $92.82 as of December 24, 2025 at a share price of $0.724.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
GlobeNewswire Inc.
Nov 21, 2025 5:25 AM GMT
These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to com
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
GlobeNewswire Inc.
Nov 05, 2025 1:00 PM GMT
SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, toda